SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-175163
Filing Date
2022-06-16
Accepted
2022-06-16 07:14:03
Documents
16
Period of Report
2022-06-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d283514d8k.htm   iXBRL 8-K 43102
2 EX-5.1 d283514dex51.htm EX-5.1 7254
3 EX-10.1 d283514dex101.htm EX-10.1 142410
4 EX-99.1 d283514dex991.htm EX-99.1 13182
8 GRAPHIC g283514g0616040528971.jpg GRAPHIC 2650
  Complete submission text file 0001193125-22-175163.txt   388268

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA akro-20220615.xsd EX-101.SCH 2857
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20220615_lab.xml EX-101.LAB 17995
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20220615_pre.xml EX-101.PRE 11262
10 EXTRACTED XBRL INSTANCE DOCUMENT d283514d8k_htm.xml XML 3357
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 221019321
SIC: 2834 Pharmaceutical Preparations